TG Therapeutics (TGTX) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating on TG Therapeutics (TGTX) today and set a price target of $20. The company’s shares opened today at $7.78.
“We continue to believe that umbralisib is a novel PI3K delta inhibitor that will be approved and launched in CLL in late 2021.”
According to TipRanks.com, White is a 5-star analyst with an average return of 17.8% and a 50.7% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.
Currently, the analyst consensus on TG Therapeutics is a Moderate Buy with an average price target of $18.50.
See today’s analyst top recommended stocks >>
Based on TG Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.16 million. In comparison, last year the company had a GAAP net loss of $41.53 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib.